Cosmc和T-合酶在黏蛋白型O-聚糖合成中的重要作用及其与人类疾病的相关性

从核心1结构（Galβ1,3GalNAcα1-O-Ser/Thr, core 1 structure, T antigen）中衍生出来的黏蛋白型O-聚糖在很多生理过程中发挥重要的生物学功能。T-合酶 （core 1 β3-galactosyltransferase, T-synthase） 是合成核心1结构的唯一糖基转移酶,它主要的功能是将半乳糖（Galactose） 添加到GalNAcα1-Ser/Thr （Tn抗原） 糖链上。但是在人体和其他脊椎动物中有活性的T-合酶的形成需要一个重要的伴侣分子Cosmc;Cosmc功能丧失将直接导致T-合酶失活,其结果是机体细胞只能合成Tn抗原以及唾液酰化Tn （sialylTn, STn, Neu5Acα2,6GalNAcα1-O-Ser/Thr）。综述目前对T-合酶和Cosmc的研究以及他们在人类疾病（如异常O-聚糖表达相关的Tn综合征、IgA肾病和肿瘤）发生发展中的作用。     

肝癌细胞系差异性表达的糖结合蛋白研究

糖结合蛋白(glycan-binding protein,GBP)在细胞生命周期中扮演着重要角色,如细胞识别、运输、免疫、代谢、增殖分化及细胞间的相互作用等.目前,对GBP的改变对细胞生物过程产生影响的研究甚少.本研究用糖芯片技术对肝癌细胞系Hep G2和正常肝细胞系L02表达的GBP进行研究;糖细胞化学验证确定差异表达GBP在肝癌细胞系中的变化和分布.结果显示,8种糖探针(如SL、LNT和Gal NAc等)和5种糖探针(如Man、Man-9-Glycan,Xyl等)分别对应的GBP在Hep G2细胞中表达上调或下调.糖细胞化学结果显示:Gal NAc识别的GBPs主要表达在Hep G2的胞膜、中央胞质、核周胞质区域,而在L02的相同区域表达减弱;Neu Ac识别的GBPs主要表达在L02的胞膜区及核周胞质区,而在Hep G2细胞的相同区域表达减弱.这些数据为寻找新的肝癌发病机制和抗肿瘤策略提供了有用信息.     

小鼠肝癌及肝正常组织B4GalT糖基转移酶家族mRNA表达差异及其对细胞膜相关糖链的影响

探讨肝癌模型鼠与正常小鼠肝组织B4GalT(β-1,4-半乳糖转移酶)家族mRNA表达差异以及对细胞膜相关糖链的影响.采用RT-PCR方法检测肝癌模型鼠和正常对照小鼠肝癌组织中B4GalT家族7个成员以及唾液酸α-2,3转移酶ST3GalⅢ、ST3GalⅣ、ST3GalⅥ、α-1,6-岩藻糖转移酶FUT8 mRNA表达差异,应用凝集素芯片检测细胞膜表面半乳糖、岩藻糖、唾液酸表达情况.结果显示:与正常对照组相比,肝癌模型鼠肝组织中B4GalT-1和B4GalT-3、ST3GalⅣ和ST3GalⅥ、FUT8呈现高表达,肝癌细胞膜半乳糖、岩藻糖、唾液酸类型糖链增加,提示B4GalT-1和B4GalT-3与肝癌细胞膜半乳糖链增加相关.由于细胞Galβ-1,4-GlcNAc糖表位在ST3GalⅢ、ST3GalⅣ或ST3GalⅥ催化下与唾液酸α-2,3连接生成s-lewis x抗原前体,本实验中B4GalT-1和B4GalT-3与ST3GalⅣ、ST3GalⅤ、FUT8 mRNA表达具有相关性,提示B4GalT-1和B4GalT-3可能与ST3GalⅣ、ST3GalⅥ以及FUT4协同作用,导致肝癌细胞膜半乳糖、岩藻糖、唾液酸类型糖链增加.     

人α-半乳糖苷酶转导克服异种移植HAR的小鼠实验研究

α 半乳糖苷酶可以特异地清除半乳糖α 1,3 半乳糖抗原 (Galα1,3Galantigen) ,此抗原是引起异种器官移植超急性排斥反应 (HyperacuteRejection ,HAR)的主要异种抗原 .将构建好的α半乳糖苷酶转基因载体通过显微注射的方式注入小鼠受精卵 ,培育出了转基因小鼠 .结果表明 ,转基因小鼠的心、肝、肾、脾、肺组织中均有人α 半乳糖苷酶基因的表达 ,其表达可以有效减少小鼠器官表面Galα1,3Gal抗原的表达水平 ,可以降低转基因小鼠脾细胞对补体介导的杀伤作用的敏感性 .研究表明人源α半乳糖苷酶基因可用于研制不表达Galα1,3Gal抗原的转基因动物 ,从而可以降低异种器官移植HAR的反应强度 ,提高移植物的存活期     

H7N2禽流感病毒HA的分离纯化及其糖链谱研究

血凝素(HA)是位于流感病毒囊膜表面的一种Ⅰ型跨膜糖蛋白,是流感病毒结合宿主细胞表面受体,介导病毒入胞的关键分子,也是中和抗体以及疫苗研制的重要靶标.HA表面糖基化与病毒毒力、感染宿主范围等密切相关,且其表面糖链变化会影响其结构与功能.然而目前关于流感病毒HA糖基化的研究主要集中在其糖基化位点上,而对于HA上详细的糖链结构知之甚少.本文应用禽流感病毒特异识别的唾液酸糖链(SAα2-3Gal)受体,制备特异的糖链磁性微粒复合物,进而从H7N2禽流感病毒中分离纯化HA,并采用SDS-PAGE及质谱技术进行鉴定.确定提取物系HA后,进一步利用凝集素芯片联合质谱技术研究禽流感病毒H7N2的HA表面糖型,结果显示H7N2禽流感病毒HA表面主要含有岩藻糖、半乳糖、N-乙酰半乳糖胺、甘露糖、N-乙酰葡糖胺等糖链结构,共获得16个糖链结构较为准确的寡糖,这些糖链可能与HA生物学功能相关.本研究有助于揭示禽流感病毒感染宿主的糖链作用机制,有助于设计制备针对HA相关的糖链疫苗.     

应用凝集素芯片分析癌细胞膜表面糖链表达

细胞膜表面糖复合物的糖链结构与肿瘤细胞增殖、侵染、转移等发展过程密切相关.凝集素芯片技术的出现实现了对癌症的糖组进行快速、高通量的检测.通过模式细胞系PANC-1证明了构建的凝集素芯片体系的准确性、重复性、特异性,应用这一芯片体系初步检测了几种癌细胞系(HT-29、SGC-7901、BEL-7402、H460)的膜表面糖链表达.这几种癌细胞系表面都有唾液酸、乙酰葡萄糖/葡萄糖、乙酰半乳糖/半乳糖、甘露糖等糖链.根据实验结果,推测它们的细胞膜表面α1-6岩藻糖链表达水平可能较高,而α1-3岩藻糖链表达水平较低;这些聚糖可能是癌症潜在的标志物.凝集素芯片有助于推动癌细胞膜表面糖链的快速分析和筛选出癌症相关的糖链标志物.     

细胞工程

<正> 852628 限定伴随人类T细胞表面糖蛋白的T细胞白血病单克隆抗体SN2[英]/Seon,B.K.…//J.Immunol.-1984,132(4)-2039～2095[译自DBA,1984,3(13),84-06314]从一个白血性T细胞系,MOLT-4的膜分离得糖蛋白,经纯化,在弗氏完全佐剂中制备成白血病抗原给小鼠腹腔注射。用聚乙二醇使免疫小鼠的脾细胞与小鼠骨髓瘤细     

应用凝集素芯片检测肝癌细胞膜表面糖链变化

利用凝集素糖链特异亲和原理构建对细胞膜表面糖链进行即时检测的凝集素芯片体系,检测肝癌发生过程中细胞膜糖链的变化.从H22细胞系、正常小鼠和肝癌模型鼠肝组织中提取细胞进行荧光标记,激光扫描仪检测凝集素位点捕获的细胞,根据凝集素特异亲和性确定细胞膜表面糖表达谱,显微镜下观察捕获细胞的形态.对凝集素芯片捕获细胞的最佳条件进行探讨,用甘露糖抑制试验、流式细胞仪和不同血型红细胞验证了凝集素捕获细胞的特异性.结果显示:正常和肝癌小鼠肝细胞膜表面糖链存在较大差异,正常组只有PSA、DSL、STL、NPL凝集素位点捕获到细胞,实验组只有LTL和DBA位点没有捕获到细胞,提示小鼠肝癌组织细胞膜表面糖链显著增加,细胞膜上唾液酸、乙酰葡萄糖、乙酰半乳糖、甘露糖和半乳糖糖链表达增加,这些糖链及其相关糖蛋白可能在肝癌的发生和发展中起一定作用.该凝集素芯片有较好的稳定性和特异性,可以对细胞膜表面糖链进行动态、即时、通量的检测,为研究细胞膜表面聚糖在细胞发育和癌变等过程中的变化提供了一个技术平台.     

CHRNA9基因绝对定量PCR标准曲线的建立

[目的]为研究乙酰胆碱受体(nicotine acetylcholine receptor,nAChR)α9亚基基因(CHRNA9)的mRNA,在人乳腺癌细胞系MCF-7和人正常乳腺上皮细胞系MCF-10A中的差异表达情况,建立了CHRNA9基因转录本拷贝数的绝对定量标准曲线。[方法]培养并收集细胞,提取总RNA,反转录合成cDNA。以cDNA为模板,扩增CHRNA9基因171bp的特征片段,亚克隆到pMD-18T载体中,并进行测序鉴定。以梯度稀释的质粒为模板,进行荧光定量PCR来建立标准曲线,进一步对上述细胞系中CHRNA9的初始拷贝数进行定量分析。[结果]成功地对人正常乳腺上皮细胞系MCF-10A,人乳腺癌细胞系MCF-7中的α9 nAChR亚基基因的mRNA水平表达量,即反转录生成的cDNA拷贝数进行了定量,mRNA拷贝数分别为712.61.31和2 236.55个。经统计分析,二者之间CHRNA9基因的表达量差异达到了极显著水平(p0.01),即α9 nAChR亚基基因在乳腺癌细胞MCF-7中显著高于乳腺正常上皮细胞MCF-10A。[结论]研究所获得的CHRNA9基因的绝对荧光定量标准曲线,可用于不同乳腺癌细胞系α9 nAChR亚基基因表达量的检测,而α9 nAChR作为一个理想的、特异性的潜在药物作用靶点,这为相应种类的乳腺癌发病机理研究和靶向治疗药物的研发提供基础。     

冠状病毒糖基化呈现的α-半乳糖表位能增强COVID-19疫苗的免疫原性

正新型冠状病毒SARS-CoV-2上的多糖链及S蛋白形成了一层聚糖屏障(glycan-shield),掩盖了抗原肽,减少了抗原呈递细胞(APC)对灭活病毒或S蛋白疫苗的摄取。对灭活流感病毒和重组HIV疫苗gp120的研究表明,糖基化聚糖屏障呈现的α-半乳糖表位(Galα1-3Galβ1-4GlcNAc-R)能够利用天然抗半乳糖抗体增强疫苗效力,这在能够产生抗半乳糖的小鼠中进行了评估。α-半乳糖表位是天然抗半乳糖抗体的配基,     

FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway

The fucosyltransferase (FUT) family is the key enzymes in cell-surface antigen synthesis during various biological processes such as tumor multidrug resistance (MDR). The aim of this work was to analyze the alteration of FUTs involved in MDR in human hepatocellular carcinoma (HCC) cell lines. Using mass spectrometry (MS) analysis, the composition profiling of fucosylated N-glycans differed between drug-resistant BEL7402/5-FU (BEL/FU) cells and the sensitive line BEL7402. Further analysis of the expressional profiles of the FUT family in three pairs of parental and chemoresistant human HCC cell lines showed that FUT4, FUT6 and FUT8 were predominant expressed in MDR cell lines. The altered levels of FUT4, FUT6 and FUT8 were responsible for changed drug-resistant phenotypes of BEL7402 and BEL/FU cells both in vitro and in vivo. In addition, regulating FUT4, FUT6 or FUT8 expression markedly modulated the activity of the phosphoinositide 3 kinase (PI3K)/Akt signaling pathway and MDR-related protein 1 (MRP1) expression. Inhibition of the PI3K/Akt pathway by its specific inhibitor wortmannin, or by Akt small interfering RNA (siRNA), resulted in decreased MDR of BEL/FU cells, partly through the downregulation of MRP1. Taken together, our results suggest that FUT4-, FUT6- or FUT8-mediated MDR in human HCC is associated with the activation of the PI3K/Akt pathway and the expression of MRP1, but not of P-gp, indicating a possible novel mechanism by which the FUT family regulates MDR in human HCC.     

Hepatitis B virus X protein modulates the apoptosis of hepatoma cell line induced by TRAIL

TRAIL (TNF-related apoptosis-inducing ligand) is one member of TNF superfamily[1]. It is unique, for it could specifically induce the apoptosis of tumor cells or virus-infected cells but have no cytotoxic effects onnormal cells[1,2]. Owing to this characteristic, it has become a promising candidate molecule for biological therapy for tumor. Many factors could affect the sensitivity towardsTRAIL-induced apoptosis, including cytokines, virus infection, drugs, radials, etc. Studies show tha…     

Hepatitis B virus X protein modulates the apoptosis of hepatoma cell line induced by TRAIL

The purpose of this study is to observe the effects of HBx on the apoptosis of hepatoma cells induced by TNF-related apoptosis-inducing ligand (TRAIL) and to study preliminary molecular mechanisms for its effects. In order to set up a modelin vitro, BEL7402-HBx cell line, stably expressing HBx mRNA, was established by stable transfection of pcDNA-HBx, which contains HBx gene, into hepatoma cell line BEL7402. Control cell line BEL7402-cDNA3, stably transfected with pcDNA3, was set up simultaneously as a control. Trypan blue exclusion test, caspase 3 activity detection and TUNEL assay were performed to detect the apoptosis of BEL7402, BEL7402-cDNA3, BEL7402-HBx induced by TRAIL. The expression of TRAIL receptors in three groups was analyzed by Flow cytometry. In addition, phosphorothioated antisense oligonucleotide against the translation initial region of HBx gene (PS-asODNs/HBx) was used to block the expression of HBx in HepG2.2.15 cells and to further confirm the effects of HBx on TRAIL-induced apoptosis. Trypan blue exclusion test indicated that TRAIL had a dose-dependent cytotoxicity on BEL7402, BEL7402-cDNA3 and BEL7402-HBx cells. Under treatment of the same concentration of TRAIL, BEL7402-HBx had a higher apoptosis rate and a higher level of Caspase 3 activation than BEL7402 and BEL7402-cDNA3. TUENL assay showed that the apoptosis rate of BEL7402-HBx induced by 10 μg/L TRAIL was 41.4%±7.2%, significantly higher than that of BEL7402 and BEL7402-cDNA3 cells. Blockade of HBx expression in Hep G2.2.15 cells partly inhibited the apoptosis induced by TRAIL. The introduction or blockade of HBx did not change the expression pattern of TRAIL receptors. The present study firstly confirms the effects of HBx on TRAIL-induced apoptosis from two different points and it is not related with the expression level of TRAIL receptors. This would be useful to further clarify the roles of imbalanced apoptosis in pathogenesis of Hepatitis B and related hepatocellular carcinoma.     

非洲马铃果4种吲哚类生物碱的体外抗肿瘤效果

为比较非洲马铃果Voacanga africana中长春胺、冠狗牙花定碱、老刺木胺、伏康京碱等4种吲哚类生物碱的体外抗肿瘤活性,采用MTT法分析其对SKOV3、BEL7402、SMMC7721、Changliver四株细胞株增殖的抑制作用,并通过AO/EB双染观察细胞凋亡的形态变化。结果显示,4种吲哚生物碱对四株细胞株的增殖抑制现象存在剂量依赖关系。50 μg·mL-1老刺木胺对四株细胞株的生长抑制率均达95%以上;相同浓度下,伏康京碱仅对BEL7402、Changliver的抑制率超过78%;冠狗牙花定碱仅对Changliver有超过50%的增殖抑制率;长春胺对四株细胞株的增殖抑制效果不明显。经AO/EB法染色后,四株细胞株在12.5 μg·mL-1老刺木胺的作用下呈现细胞核皱缩、浓聚和偏移的现象,说明老刺木胺具有明显诱导细胞凋亡的作用;50 μg·mL-1伏康京碱仅对BEL7402和Changliver具有一样的效果,另两种生物碱作用的细胞株并未见有明显的细胞凋亡现象。MTT法和AO/EB双染法表现结果一致。老刺木胺和伏康京碱两种生物碱能够诱导卵巢癌细胞和人肝细胞凋亡从而发挥抗肿瘤作用,长春胺和冠狗牙花定碱作用效果相对较弱。     

药用昆虫蜣螂对灵芝发酵产物体外抗肿瘤活性的影响

采用体外高通量筛选技术检测了补加药用昆虫蜣螂前后灵芝发酵产物的体外抗肿瘤活性。结果表明,补加和不补加蜣螂发酵后所得的胞内和胞外三萜样品对肉瘤细胞L290、肠癌细胞SW620、血癌细胞K562和肝癌细胞BEL7402都有显著的抑制作用(P<0.05)。在补加蜣螂发酵后,灵芝胞内三萜的抑制作用没有得到增强;但胞外三萜样品对BEL7402细胞的抑制作用得到了增强,补加和不补加蜣螂发酵后所得胞外三萜的抑制率分别为41.74%和32.37%(P<0.05)。由于补加蜣螂发酵后,新生成了胞外三萜lucidone C,因而对lucidone C的抗BEL7402肝癌活性进行了试验。结果显示,lucidone C在100μg/mL时,对BEL7402的抑制率为50.37%,提示lucidone C可能增强了补加蜣螂后灵芝胞外总三萜对BEL7402细胞的抑制作用。     

紫芝酸性三萜类化合物体外抑癌和抑菌作用的研究

采用噻唑蓝比色(MTT)法研究紫芝酸性三萜对几种癌细胞体外增殖的影响,并用管碟法检测了紫芝胞内酸性三萜对几种细菌和霉菌的体外抑菌作用。结果表明,紫芝胞内酸性三萜和胞外酸性三萜在250μg/mL时,对人肝癌细胞BEL7402和人乳腺癌细胞MCF-7均有显著抑制作用(P<0.05),但对人胃癌细胞SGC-7901没有显著抑制作用(P>0.05)。BEL7402细胞的生长曲线试验表明,胞内酸性三萜组的细胞受到显著抑制,未出现指数增长期,且BEL7402细胞培养3d后,对照组细胞数目多、均匀,而胞内酸性三萜组的细胞数目明显减少,且细胞变小。抑菌试验结果表明,胞内酸性三萜在40mg/mL时,对大肠杆菌Escherichia coli和金黄色葡萄球菌Staphylococcus aureus的生长均具有显著抑制作用(P<0.01),对枯草芽孢杆菌Bacillus subtitis和青霉的Penicillium chrysogenum抑制作用较弱;而在此浓度下对黑曲霉Aspergillus niger没有抑制作用。该样品对大肠杆菌、金黄色葡萄球菌、枯草芽孢杆菌、黑曲霉和青霉的MIC分别为20mg/mL、20mg/mL、40mg/mL、80mg/mL和40mg/mL。此外,该酸性三萜的抑菌成分在60℃下(处理2h)较稳定,但在80℃以上,热稳定性较差,活性降低。     

健脾化瘀中药提高胞嘧啶脱氨酶/单纯疱疹病毒胸苷激酶基因治疗肝细胞癌的实验研究

目的:观察健脾化瘀中药提高胞嘧啶脱氨酶/单纯疱疹病毒胸苷激酶基因治疗肝细胞癌的作用。方法:脂质体lipofectamine将含有双自杀基因的腺病毒载体pAd-CD/TK导人293细胞,收集病毒上清转染人肝癌细胞BEL7402,MTT法测定BEL7402细胞存活率。裸鼠人肝癌模型转染CD/TK双自杀基因后,给予5-FC500mg/kg,GCV 100mg/kg腹腔注射,同时予健脾化瘀中药960复方灌胃。观察肿瘤生长情况。结果:给予前体药物5-FC和GCV后,CD/TK转染细胞被杀死。并表现出较强的旁观者效应。转染细胞比例达到10%即表现出较强的杀伤作用(P<0.01)。健脾化瘀中药960复方具有提高旁观者效应作用,1.67ml/kg和2.5ml/kg960复方含药血清组细胞存活率显著低于对照组(P<0.01)。转染基因组应用5-FC和GCV治疗后,裸鼠肝癌的生长明显受到抑制(P<0.05),抑瘤率39.42%,单用中药组抑瘤率18.04%,中药与CD/TK 5-FC/GCV联合运用组,较单纯CD/5-FC/HSV-tk/GCV对裸鼠肿瘤模型的生长抑制作用更加明显(P<0.05),抑瘤率55.10%。结伦:腺病毒介导CD/TK自杀基因可有效地杀死人肝癌BEL7402细胞,健脾化瘀中药960复方具有显著提高CD/TK双自杀基因对人肝癌细胞的抑杀作用。     

Proteomic investigation of 5-fluorouracil resistance in a human hepatocellular carcinoma cell line

Multi-drug resistance (MDR) is a major obstacle towards a successful treatment of hepatocellular carcinoma (HCC). The mechanisms of MDR are intricate and have not been fully understood. Therefore, we employed a cell-line model consisting of the 5-fluorouracil (5-FU) resistant BEL7402/5-FU cell line and its parental BEL7402 cell line. Using relative and absolute quantification (iTRAQ)-coupled 2D LC-MS/MS, a successfully exploited high-throughput proteomic technology, in total, 660 unique proteins were identified and 52 proteins showed to be differentially expressed in BEL7402/5-FU compared with BEL7402. Several differentially expressed proteins were further validated by Western blot and real-time quantitative RT-PCR analysis. Furthermore, the association of MDR with ANXA3, one of the highly expressed proteins in BEL7402/5-FU, was verified. Our study represents the first successful application of iTRAQ technology for MDR mechanisms analysis in HCC. Many of the differentially expressed proteins identified had not been linked to MDR in HCC before, which provide valuable information for further understanding of MDR.     

The development, characterization, and demonstration of a novel strategy for purification of recombinant proteins expressed in plants

Plants have attracted increasing attention as an expression platform for the production of pharmaceutical proteins due to its unlimited scalability and low cost potential. However, compared to other expression systems, plants accumulate relatively low levels of foreign proteins, thus necessitating the development of efficient systems for purification of foreign proteins from plant tissues. We have developed a novel strategy for purification of recombinant proteins expressed in plants, based on genetic fusion to soybean agglutinin (SBA), a homotetrameric lectin that binds to N-acetyl-D-galactosamine. Previously it was shown that high purity SBA could be recovered from soybean with an efficiency of greater than 90% following one-step purification using N-acetyl-D-galactosamine-agar columns. We constructed an SBA fusion protein containing the reporter green fluorescent protein (GFP) and transiently expressed it in N. benthamiana plants. We achieved over 2.5% of TSP accumulation in leaves of N. benthamiana. Confocal microscopic analysis demonstrated in vivo activity of the fused GFP partner. Importantly, high purity rSBA-GFP was recovered from crude leaf extract with ~90% yield via one-step purification on N-acetyl-D-galactosamine-agar columns, and the purified fusion protein was able to induce the agglutination of rabbit red blood cells. Combined with this, tetrameric assembly of the fusion protein was demonstrated via western blotting. In addition, rSBA-GFP retained its GFP signal on agglutinated red blood cells, demonstrating the feasibility of using rSBA-GFP for discrimination of cells that bear the ligand glycan on their surface. This work validates SBA as an effective affinity tag for simple and rapid purification of genetically fused proteins.